This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Masimo (MASI) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Masimo Shares Dip Despite FDA Clears Expanded Use of O3 Monitoring
by Zacks Equity Research
MASI gains FDA clearance to expand O3 monitoring with delta hemoglobin parameters across all patient groups.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
3 Reasons Why Growth Investors Shouldn't Overlook Masimo (MASI)
by Zacks Equity Research
Masimo (MASI) is well positioned to outperform the market, as it exhibits above-average growth in financials.
MASI Stock Slips Despite Q2 Earnings and Revenue Beat, Margins Expand
by Zacks Equity Research
Masimo's second-quarter 2025 performance beats earnings and revenue estimates, expands margins and lifts 2025 outlook.
Masimo (MASI) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Masimo (MASI) delivered earnings and revenue surprises of +8.13% and +0.59%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Is Masimo (MASI) a Solid Growth Stock? 3 Reasons to Think "Yes"
by Zacks Equity Research
Masimo (MASI) could produce exceptional returns because of its solid growth attributes.
COR Q2 Earnings & Revenues Beat Estimates, '25 EPS Guidance Raised
by Zacks Equity Research
COR's second-quarter fiscal 2025 results showcase a strong segmental performance. The company's earnings guidance for fiscal 2025 looks encouraging.
MASI Stock Slips Despite Q1 Earnings and Revenue Beat, Margins Expand
by Zacks Equity Research
Masimo's first-quarter 2025 results continue to benefit from the strength in its Healthcare businesses despite tariff-related uncertainties.
Omnicell Q1 Earnings & Revenues Beat, '25 EPS View Down, Stock Up
by Zacks Equity Research
OMCL posts better-than-expected top and bottom-line results for the first quarter of 2025.
Masimo (MASI) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Masimo (MASI) delivered earnings and revenue surprises of 9.68% and 1.29%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
NVST Stock Up on Q1 Earnings and Revenue Beat, Margins Crash
by Zacks Equity Research
Envista delivers better-than-expected top and bottom-line results for the first quarter of 2025.
ZBH Q1 Earnings Beat, Operating Margin Dips, Stock Down in Premarket
by Zacks Equity Research
Zimmer Biomet reports solid first-quarter performance across its geographic regions. However, contraction in its operating margin is a concern.
Watch These 3 MedTech Stocks for Q1 Earnings: Beat or Miss?
by Debanjana Dey
MedTech companies' quarterly results are likely to reflect strength in customer demand. Let's see how FMS, MASI and CLOV are placed ahead of their earnings releases.
Teleflex Q1 Earnings Beat, '25 EPS View Down, Stock Up
by Zacks Equity Research
TFX benefits from a diversified product portfolio in the first quarter of 2025, with strength in the Surgical and Interventional segments.
SYK Stock Falls Despite Q1 Earnings & Sales Beat on Lower '25 EPS View
by Zacks Equity Research
SYK's first-quarter results reflect strong segmental performance, along with a rise in operating margin.
DexCom Stock Rises Despite Q1 Earnings Miss & Lower Margins
by Zacks Equity Research
DXCM's first-quarter 2025 earnings decline despite increasing sales. Its performance in 2025 is expected to be fueled by global growth in CGM adoption, strong Sensor sales and expansion into new markets.
TNDM Stock Rises Despite Q1 Earnings Miss, Gross Margin Up
by Zacks Equity Research
Tandem Diabetes' Q1 bottom line lags estimate. However, the company experiences strong sales growth both in and outside the United States.
BIO Beats on Q1 Earnings, Lowers '25 View, Stock Up in Aftermarket
by Zacks Equity Research
Bio-Rad witnesses first-quarter top-line decline in its Life Science segment, primarily due to challenges in the academic research market.
BAX Stock Gains Following Q1 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Baxter reports better-than-expected first-quarter results. However, the company's gross margin contracts. Shares rise in pre-market.
ARAY Stock Down Despite Q3 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Accuray reports solid fiscal third-quarter results, witnessing growth in Product & Services revenues and reduced operating expenses.
GKOS Stock Falls Despite Q1 Earnings & Revenue Beat, Margins Decline
by Zacks Equity Research
Glaukos' first-quarter results showcase a strong uptick in revenues. However, continued operating loss remains a cause of concern.
CAH Q3 Earnings Beat Estimates, '25 EPS View Raised, Stock Gains
by Zacks Equity Research
Cardinal Health's third-quarter fiscal 2025 results benefit from solid Medical and Other segment revenue growth. However, OptumRx contract expiry hurts Pharmaceutical segment sales.
IDXX Q1 Earnings Beat, FY25 View Raised, Stock Up in Pre-Market
by Zacks Equity Research
IDEXX delivers year-over-year earnings and revenue growth in the first quarter of 2025.
CNMD Stock Up On Q1 Earnings & Sales Beat, Raised 2025 Outlook
by Zacks Equity Research
CNMD reports solid first-quarter results, driven by improving sales across both segments.